Ocrevus Still Reigns for Progressive MS, Spherix Reports, But Challenges Noted
From: Multiple Sclerosis News Today By: Marta Figueiredo Genentech’s Ocrevus (ocrelizumab) continues to be the most prescribed treatment for people with progressive forms of multiple sclerosis (MS) among U.S. neurologists, according to the latest Spherix Global Insights’ report…(read more).
Genentech’s Ocrevus Dominates the Progressive Multiple Sclerosis Market, Although Emerging Agents Could Threaten its Long-Term Reign, According to Patient Chart Data from Spherix Global Insights
Will impressive uptake of Novartis’ Mayzent in the active secondary progressive multiple sclerosis market over the past two years be enough to unseat Ocrevus in the US? EXTON, Pa., October 27, 2020/PRNewswire/ — While the segment of multiple sclerosis (MS) patients with progressive disease remains underserved, numerous recent approvals for relapsing MS (RMS)—including active secondary […]
Ocrevus Use Still Growing in Europe But Challenges on Horizon, Spherix Reports
From: Multiple Sclerosis News Today By: Marta Figueiredo Prescriptions of Roche’s Ocrevus (ocrelizumab) among multiple sclerosis (MS) patients initiating or switching a disease-modifying…
Newest Oral DMTs Haven’t Yet Made a Big Impact in the MS World
From: MDedge Neurology By: Bruce Jancin The three oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) approved last year in the United States haven’t made a big splash in…
Want to Try Emgality? What You Should Know
From: MigraineAgain By: Lori Smith At this time, there is no safety reason for not allowing people to try both Botox and Emgality at the same time. According to Virginia Schobel, Neurology Franchise Head at Spherix Global Insights…(read more).
Gilenya Remains Favorite S1P Receptor Modulator in US, But Zeposia May Catch Up, Survey Finds
From: Multiple Sclerosis News Today By: Marta Figueiredo Among oral sphingosine-1-phosphate (S1P) receptor modulators for multiple sclerosis (MS), Novartis’s Gilenya (fingolimod) remains physicians’ favorite in the U.S., but prescriptions of recently-launched Bristol Myers Squibb’s Zeposia (ozanimod) are beginning to rise, according to a survey conducted by Spherix Global Insights…(read more).
Following a Delayed Launch, Bristol Myers Squibb’s Zeposia has Begun to Successfully Establish Itself as a Low-Burden Option Within the S1P Receptor Modulator Class, According to Spherix Global Insights
Spherix’s new launch tracking service will further monitor details of Zeposia’s uptake over 18 months and benchmark key metrics against historical launches, including Genentech’s Ocrevus and Novartis’ Mayzent EXTON, Pa., September 16, 2020 /PRNewswire/ — With expanded use of new oral disease-modifying therapies (DMTs) in the multiple sclerosis (MS) market, oral DMT class share has […]
Despite Most Specialty Physician Practices Reopening, Engagement with the Pharmaceutical Industry Continues to be Largely Virtual, Placing Added Pressure on Manufacturers Attempting to Introduce New Therapies
Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains EXTON, Pa., September 15, 2020 / PRNewswire / – In March, Spherix began tracking the impact of COVID-19 among specialty physicians, specifically dermatologists, gastroenterologists, nephrologists, neurologists, and rheumatologists. In each wave, approximately 250 specialists share […]
Spherix Global Insights Releases 2021 Publication Plan and Announces New Service, Launch Dynamix™, Fueled by Growing Client Demand
The firm, which was recently recognized by Philadelphia Business Journal as one of the area’s Soaring 76 fastest growing companies for the second year in a row, continues to invest in its areas of deep expertise: dermatology, gastroenterology, nephrology, neurology, and rheumatology EXTON, Pa., August 27, 2020 /PRNewswire/ — Since its founding in 2015, Spherix […]
Recent Label Revisions Related to Constipation and Hypertension Generate Minimal Drag on the Decision to Prescribe Amgen/Novartis’ Aimovig as a Preventive Treatment for Migraine
The recent launch of Teva’s Ajovy autoinjector appears to be paying dividends, while market access and autoinjector preference are no longer distinct points of differentiation for Eli Lilly’s Emgality, according to Spherix Global Insights’ most recent patient chart audit EXTON, Pa., August 18, 2020/PRNewswire/ — Distinctive prescribing patterns and drivers of brand selection among the […]
